Trial Profile
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Graft-versus-host disease; Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms Cninical Trial BP-I-008
- Sponsors Bellicum Pharmaceuticals
- 08 Mar 2024 This study has been Discontinued in Italy, According to European Clinical Trials Database record.
- 01 Oct 2020 Planned End Date changed from 1 Dec 2034 to 1 Jan 2033.
- 24 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2034.